Fig. 6: mAb treatment of Syrian hamsters before and after PIV3 challenge. | Nature Communications

Fig. 6: mAb treatment of Syrian hamsters before and after PIV3 challenge.

From: The structural basis of protective and nonprotective human monoclonal antibodies targeting the parainfluenza virus type 3 hemagglutinin-neuraminidase

Fig. 6

A Syrian hamsters (n = 10) were treated with 10 mg/kg of one mAb binding to each identified site on HN 24 h prior to the intranasal PIV3 challenge. Lungs were collected four days following the viral challenge. Created in BioRender. Miller, R. (2024) https://BioRender.com/w46b621. B Plaque assays revealed decreased viral load in the lungs with prophylactically PIV05- and PIV09-treated hamsters. Data are presented as mean values. Statistical significance was calculated using a one-sided ANOVA for multiple comparisons (***P = 0.0002, *P = 0.02). C Syrian hamsters (n = 5) were treated 24 hours after the intranasal PIV3 challenge. Lungs were collected four days following the viral challenge. Created in BioRender. Miller, R. (2024) https://BioRender.com/y64f007. D Viral load in the lungs of PIV05 was significantly lower than in the mock-treated group. Data are presented as mean values. Statistical significance was calculated using a one-sided ANOVA for multiple comparisons (**P = 0.007, *P = 0.04).

Back to article page